Lista de obras - Julie Charles - Dominio Público Uruguay

A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells

artículo científico publicado en 2010

Acantholytic dermatosis in patients treated by vemurafenib: 2 cases

artículo científico publicado en 2014

Access to molecular guided therapy for Langerhans cell histiocytosis patients

artículo científico publicado en 2015

An "anaplastic" Kaposi's sarcoma mimicking a Stewart-Treves syndrome. A case report and a review of literature.

artículo científico publicado en 2008

Anti-PD1-induced psoriasis: a study of 21 patients

artículo científico publicado en 2016

BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients

artículo científico publicado en 2020

Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor

artículo científico publicado en 2010

Characterization of foreign materials in paraffin-embedded pathological specimens using in situ multi-elemental imaging with laser spectroscopy

artículo científico publicado en 2017

Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses

artículo científico publicado en 2017

Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes

artículo científico publicado en 2021

Exogenous human herpesvirus 6 reinfection after tumor-infiltrating T-lymphocyte therapy.

artículo científico publicado en 2018

Fixed drug eruption caused by fulvestrant confirmed by skin tests: First case

artículo científico publicado en 2018

HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients.

artículo científico publicado en 2012

Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms

artículo científico publicado en 2016

Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma

artículo científico publicado en 2013

Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.

artículo científico publicado en 2014

Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma

artículo científico publicado en 2017

Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.

artículo científico publicado en 2014

Mechanisms of resistance to anti-BRAF treatments

artículo científico publicado en 2014

Melanoma hijacks plasmacytoid dendritic cells to promote its own progression.

artículo científico

Mesalazine and para-phenylenediamine allergy.

artículo científico publicado en 2004

Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation

artículo científico publicado en 2019

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

article

Nivolumab in previously untreated melanoma without BRAF mutation

artículo científico publicado en 2015

Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.

artículo científico publicado en 2017

Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer.

scientific article published on 22 October 2009

Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL.

artículo científico publicado en 2013

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

scientific article published on 01 February 2019

The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients

artículo científico publicado en 2017

Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson's disease

artículo científico publicado en 2009

[CDKN2A gene mutation and loss of p16 protein activity in a patient on levodopa presenting sporadic multiple primary melanoma]

artículo científico publicado en 2006

[Certolizumab]

artículo científico publicado en 2019

[GENiusVac, a novel antitumor vaccine strategy based on allogeneic plasmacytoid dendritic cells]

artículo científico publicado en 2011

[Reprint of: Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie]

artículo científico publicado en 2018

[Syringotropic and pilotropic cutaneous T-cell lymphoma without follicular mucinosis]

scientific article published on 01 February 2007

[Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie]

artículo científico publicado en 2018

Lista de obras de Julie Charles

A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells

Acantholytic dermatosis in patients treated by vemurafenib: 2 cases

Access to molecular guided therapy for Langerhans cell histiocytosis patients

An "anaplastic" Kaposi's sarcoma mimicking a Stewart-Treves syndrome. A case report and a review of literature.

Anti-PD1-induced psoriasis: a study of 21 patients

BDCA1<sup>+</sup> cDC2s, BDCA2<sup>+</sup> pDCs and BDCA3<sup>+</sup> cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients

Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor

Characterization of foreign materials in paraffin-embedded pathological specimens using in situ multi-elemental imaging with laser spectroscopy

Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses

Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes

Exogenous human herpesvirus 6 reinfection after tumor-infiltrating T-lymphocyte therapy.

Fixed drug eruption caused by fulvestrant confirmed by skin tests: First case

HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients.

Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms

Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma

Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.

Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma

Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.

Mechanisms of resistance to anti-BRAF treatments

Melanoma hijacks plasmacytoid dendritic cells to promote its own progression.

Mesalazine and para-phenylenediamine allergy.

Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

Nivolumab in previously untreated melanoma without BRAF mutation

Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.

Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer.

Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients

Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson's disease

[CDKN2A gene mutation and loss of p16 protein activity in a patient on levodopa presenting sporadic multiple primary melanoma]

[Certolizumab]

[GENiusVac, a novel antitumor vaccine strategy based on allogeneic plasmacytoid dendritic cells]

[Reprint of: Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie]

[Syringotropic and pilotropic cutaneous T-cell lymphoma without follicular mucinosis]

[Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie]